This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Reata Pharmaceuticals Management

Management criteria checks 4/4

Reata Pharmaceuticals' CEO is J. Huff, appointed in Jan 2002, has a tenure of 21.67 years. total yearly compensation is $1.11M, comprised of 57.5% salary and 42.5% bonuses, including company stock and options. directly owns 0.81% of the company’s shares, worth $53.34M. The average tenure of the management team and the board of directors is 3.9 years and 4.8 years respectively.

Key information

J. Huff

Chief executive officer

US$1.1m

Total compensation

CEO salary percentage	57.5%
CEO tenure	21.7yrs
CEO ownership	0.8%
Management average tenure	3.9yrs
Board average tenure	4.8yrs

Recent management updates

Recent updates

Here's Why We're Not At All Concerned With Reata Pharmaceuticals' (NASDAQ:RETA) Cash Burn Situation

May 10

FDA to not hold advisory committee meeting for Reata Pharma's Friedreich's ataxia drug

Oct 13

Will Reata Pharmaceuticals (NASDAQ:RETA) Spend Its Cash Wisely?

Oct 12

Reata Pharmaceuticals Q2 2022 Earnings Preview

Aug 05

We Think Reata Pharmaceuticals (NASDAQ:RETA) Can Afford To Drive Business Growth

Jun 22

Reata Pharmaceuticals: Once Beaten, Twice Shy

Mar 28

Reata's Advisory Committee Hiccup Ruins Its Future Prospects

Dec 31

Here's Why We're Not Too Worried About Reata Pharmaceuticals' (NASDAQ:RETA) Cash Burn Situation

Dec 23

CEO Compensation Analysis

How has J. Huff's remuneration changed compared to Reata Pharmaceuticals's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2023	n/a	n/a	-US$88m
Mar 31 2023	n/a	n/a	-US$354m
Dec 31 2022	US$1m	US$636k	-US$312m
Sep 30 2022	n/a	n/a	-US$312m
Jun 30 2022	n/a	n/a	-US$305m
Mar 31 2022	n/a	n/a	-US$304m
Dec 31 2021	US$4m	US$636k	-US$297m
Sep 30 2021	n/a	n/a	-US$278m
Jun 30 2021	n/a	n/a	-US$271m
Mar 31 2021	n/a	n/a	-US$266m
Dec 31 2020	US$6m	US$636k	-US$248m
Sep 30 2020	n/a	n/a	-US$369m
Jun 30 2020	n/a	n/a	-US$343m
Mar 31 2020	n/a	n/a	-US$310m
Dec 31 2019	US$6m	US$579k	-US$290m
Sep 30 2019	n/a	n/a	-US$129m
Jun 30 2019	n/a	n/a	-US$120m
Mar 31 2019	n/a	n/a	-US$114m
Dec 31 2018	US$935k	US$534k	-US$81m
Sep 30 2018	n/a	n/a	-US$72m
Jun 30 2018	n/a	n/a	-US$53m
Mar 31 2018	n/a	n/a	-US$36m
Dec 31 2017	US$5m	US$514k	-US$48m
Sep 30 2017	n/a	n/a	-US$35m
Jun 30 2017	n/a	n/a	-US$24m
Mar 31 2017	n/a	n/a	-US$13m
Dec 31 2016	US$5m	US$450k	-US$6m

Compensation vs Market: J.'s total compensation ($USD1.11M) is below average for companies of similar size in the US market ($USD8.17M).

Compensation vs Earnings: J.'s compensation has been consistent with company performance over the past year.

CEO

J. Huff (69 yo)

21.7yrs

Tenure

US$1,106,699

Compensation

Mr. J. Warren Huff has been the Chief Executive Officer of Reata Pharmaceuticals, Inc. (formerly, Reata Discovery Inc) and has been its Chairman since 2002 and serves as its Secretary since May 2023. He ha...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
J. Huff	Chairman	21.7yrs	US$1.11m	0.81% $ 53.3m
Manmeet Soni	COO, CFO & President	4.1yrs	US$4.00m	0.020% $ 1.3m
Michael Wortley	Executive VP and Chief Legal & Compliance Officer	8.4yrs	US$2.86m	0.031% $ 2.1m
Colin Meyer	Executive VP & Chief Innovation Officer	no data	US$2.93m	0.41% $ 26.9m
Dawn Bir	Executive VP & Chief Commercial Officer	7yrs	US$2.74m	0.093% $ 6.1m
Bhaskar Anand	Senior VP & Chief Accounting Officer	1.8yrs	no data	0.025% $ 1.7m
W. Wigley	Senior VP & Chief Scientific Officer	3.7yrs	no data	no data
Steve Harman	Senior VP & Chief Human Resources Officer	4.4yrs	no data	no data
Samina Khan	Chief Medical Officer & Senior VP	3.2yrs	no data	0.013% $ 869.4k
Dakota Gallivan	VP & Chief Healthcare Compliance Officer	3.2yrs	no data	no data
Andrea Loewen-Rodriguez	Senior Vice President of Global Regulatory Affairs	no data	no data	0.075% $ 4.9m
Rajiv Patni	Executive VP and Chief Research & Development Officer	less than a year	no data	no data

3.9yrs

Average Tenure

54yo

Average Age

Experienced Management: RETA's management team is considered experienced (3.9 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
J. Huff	Chairman	21.7yrs	US$1.11m	0.81% $ 53.3m
Martin Edwards	Independent Director	3.1yrs	US$353.43k	0% $ 0
William Rose	Independent Director	7.6yrs	US$349.91k	6.72% $ 441.1m
Richard McGaughy	Lead Independent Director	18.8yrs	US$391.34k	0.96% $ 62.7m
William McClellan	Independent Director	6.5yrs	US$381.87k	0% $ 0
Steven Ryder	Independent Director	1.2yrs	US$575.12k	0.016% $ 1.1m
Christy Oliger	Independent Director	2.4yrs	US$344.94k	0.010% $ 659.9k
Shamim Ruff	Independent Director	2.4yrs	US$361.34k	0.014% $ 900.3k

4.8yrs

Average Tenure

63yo

Average Age

Experienced Board: RETA's board of directors are considered experienced (4.8 years average tenure).

This company has been acquired

Reata Pharmaceuticals Management

Management criteria checks 4/4

Key information

Recent management updates

Insider recently sold US$546k worth of stock

Insider notifies of intention to sell stock

Executive VP & Chief Innovation Officer recently sold US$463k worth of stock

COO, CFO & President notifies of intention to sell stock

COO, CFO & President recently sold US$6.0m worth of stock

COO, CFO & President notifies of intention to sell stock

Recent updates

Reata Pharmaceuticals, Inc.(NasdaqGM:RETA) dropped from NASDAQ Composite Index

Biogen Inc. (NasdaqGS:BIIB) acquired Reata Pharmaceuticals, Inc. (NasdaqGM:RETA).

Insider recently sold US$546k worth of stock

Insider notifies of intention to sell stock

Executive VP & Chief Innovation Officer recently sold US$463k worth of stock

Sanofi Reportedly Second Bidder for Reata

Consensus revenue estimates increase by 60%

Consensus revenue estimates increase by 67%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

COO, CFO & President notifies of intention to sell stock

New major risk - Share price stability

Biogen Inc. (NasdaqGS:BIIB) entered into a definitive agreement to acquire Reata Pharmaceuticals, Inc. (NasdaqGM:RETA) from shareholders for approximately $7 billion.

Price target increased by 8.5% to US$125

Reata Pharmaceuticals, Inc. Announces Approval of Prior Approval Supplement for SKYCLARYS®? (Omaveloxolone) and Commercial Availability of SKYCLARYS for Patients with Friedreich's Ataxia

Reata Pharmaceuticals, Inc.(NasdaqGM:RETA) dropped from Russell 2000 Growth Index

COO, CFO & President recently sold US$6.0m worth of stock

COO, CFO & President notifies of intention to sell stock

Reata Pharmaceuticals Appoints Rajiv Patni as Executive Vice President, Chief Research & Development Officer

Insider recently sold US$616k worth of stock

Consensus revenue estimates increase by 27%, EPS downgraded

Forecast to breakeven in 2025

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Here's Why We're Not At All Concerned With Reata Pharmaceuticals' (NASDAQ:RETA) Cash Burn Situation

Executive VP & Chief Commercial Officer recently sold US$808k worth of stock

Executive VP & Chief Commercial Officer recently sold US$630k worth of stock

Executive VP & Chief Innovation Officer exercised options and sold US$7.7m worth of stock

Forecast to breakeven in 2025

Consensus revenue estimates increase by 18%, EPS downgraded

Price target increased by 75% to US$104

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target increased to US$59.50

Consensus forecasts updated

Price target increased to US$59.50

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Reata Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 08, 2022

FDA to not hold advisory committee meeting for Reata Pharma's Friedreich's ataxia drug

Will Reata Pharmaceuticals (NASDAQ:RETA) Spend Its Cash Wisely?

Consensus forecasts updated

Price target decreased to US$50.67

Reata Pharmaceuticals Announces Three Month Extension of the Review Period for New Drug Application for Omaveloxolone for the Treatment of Friedreich’s Ataxia

Second quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Reata Pharmaceuticals Q2 2022 Earnings Preview

Reata Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Reata Pharmaceuticals, Inc. Announces the Appointment of Steven W. Ryder, M.D. to Board of Directors

We Think Reata Pharmaceuticals (NASDAQ:RETA) Can Afford To Drive Business Growth

Reata Pharmaceuticals, Inc. Announces Retirement of Jack B. Nielsen from Board of Directors

Reata Pharmaceuticals Announces U.S. Food and Drug Administration Filing Acceptance

Consensus forecasts updated

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Reata Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 10, 2022

Reata Pharmaceuticals, Inc., Annual General Meeting, Jun 08, 2022

Price target increased to US$59.67

Reata Pharmaceuticals Completes Rolling Submission of New Drug Application to the U.S. Food and Drug Administration for Omaveloxolone for the Treatment of Patients with Friedreich’s Ataxia

Reata Pharmaceuticals: Once Beaten, Twice Shy

Price target increased to US$62.75

Reata Pharmaceuticals, Inc. Notifies Jack B. Nielsen's Intention to Retire from the Board

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

No longer forecast to breakeven

Reata Pharmaceuticals Receives Complete Response Letter from the FDA for Bardoxolone for the Treatment of Patients with Chronic Kidney Disease Caused by Alport Syndrome

Reata Pharmaceuticals, Inc. to Report Q4, 2021 Results on Feb 28, 2022

Reata Pharmaceuticals, Inc. Announces Executive Changes

Pomerantz LLP Files Class Action Lawsuit Against Reata Pharmaceuticals, Inc

Block & Leviton LLP Files Class Action Lawsuit Against Reata Pharmaceuticals, Inc. for Securities Fraud, Expanding the Class Period

Reata's Advisory Committee Hiccup Ruins Its Future Prospects

Here's Why We're Not Too Worried About Reata Pharmaceuticals' (NASDAQ:RETA) Cash Burn Situation

Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Reata Pharmaceuticals, Inc. (RETA) Investors

CEO Compensation Analysis

CEO